Priedigkeit, Nolan
Ding, Kai
Horne, William
Kolls, Jay K.
Du, Tian
Lucas, Peter C.
Blohmer, Jens-Uwe
Denkert, Carsten
Machleidt, Anna
Ingold-Heppner, Barbara
Oesterreich, Steffi
Lee, Adrian V. http://orcid.org/0000-0001-9917-514X
Article History
Received: 10 September 2020
Accepted: 4 December 2020
First Online: 6 January 2021
Ethics approval and consent to participate
: Institutional Review Board approval from both participating institutions (University of Pittsburgh IRB# PRO15050502, The Charité IRB Office) was obtained prior to initiating the study.
: All authors consented to the publication of the study as presented.
: Illumina provided free reagents for the study but had no role in the study design, data analysis, or conclusions. AVL is on the Scientific Advisory Board and a stockholder in Ocean Genomics. CD reports personal fees from Novartis, Roche, MSD Oncology, and Daiichi Sankyo and grants from Myriad Genetics and is a shareholder of Sividon Diagnostics/Myriad. In addition, Dr. Denkert has a patent EP18209672 pending, a patent EP20150702464 pending, and a patent Software (VMscope digital pathology) pending. JUB has received Honoraria from Amgen, AstraZeneca, Pfizer, Novartis, SonoScape, MSD Oncology, and Roche and has served a consulting role for Pfizer, Amgen, Novartis, AstraZeneca, and Roche.